Ocuphire Pharma Investor Day Presentation Deck

DR DME 35 Takeaways: Masked Interim Safety Findings from ZETA-1 Trial ● ~70% completion of enrollment in 24-week ZETA-1 Phase 2b Trial No major organ toxicities (liver, heart, kidney, brain, lung) or vital sign abnormalities (blood pressure or heart rate) were observed Incidence of mild rash and diarrhea in the diabetic patient population is lower than previously observed in hepatitis patients Review of masked safety data for 600 mg/day daily dose is consistent with the favorable safety profile seen in previous studies with APX3330 ZETA-1 Clinical Trial Ocuphire PHARMA

View entire presentation